GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Conforti A, Cifuentes-González C, Agrawal KR, Agrawal R

Open source

DOI
10.1016/j.drudis.2026.104786
Published
2026 Sep
Container
Drug discovery today
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.drudis.2026.104786,
  title = {GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.},
  author = {Conforti A and Cifuentes-González C and Agrawal KR and Agrawal R},
  year = {2026},
  journal = {Drug discovery today},
  doi = {10.1016/j.drudis.2026.104786},
  url = {https://doi.org/10.1016/j.drudis.2026.104786}
}

RIS

TY  - JOUR
TI  - GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.
AU  - Conforti A
AU  - Cifuentes-González C
AU  - Agrawal KR
AU  - Agrawal R
PY  - 2026
JO  - Drug discovery today
DO  - 10.1016/j.drudis.2026.104786
UR  - https://doi.org/10.1016/j.drudis.2026.104786
ER  - 

APA

A, C., C, C., KR, A., & R, A. (2026). GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.. Drug discovery today. https://doi.org/10.1016/j.drudis.2026.104786

Source records